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hronic calorie restriction has been
known for decades to prevent or
retard cancer growth, but its weight-loss
effect and the potential problems associated with combining it with chemotherapy have prevented its clinical application.
Based on the discovery in model organisms that short term starvation (STS or
fasting) causes a rapid switch of cells to
a protected mode, we described a fastingbased intervention that causes remarkable
changes in the levels of glucose, IGF-I and
many other proteins and molecules and is
capable of protecting mammalian cells
and mice from various toxins, including chemotherapy. Because oncogenes
prevent the cellular switch to this stress
resistance mode, starvation for 48 hours
or longer protects normal yeast and mammalian cells and mice but not cancer cells
from chemotherapy, an effect we termed
Differential Stress Resistance (DSR). In
a recent article, ten patients who fasted
in combination with chemotherapy,
reported that fasting was not only feasible and safe but caused a reduction in a
wide range of side effects accompanied by
an apparently normal and possibly augmented chemotherapy efficacy. Together
with the remarkable results observed in
animals, these data provide preliminary
evidence in support of the human application of this fundamental biogerontology
finding, particularly for terminal patients
receiving chemotherapy. Here we briefly
discuss the basic, pre-clinical and clinical
studies on fasting and cancer therapy.
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After decades of slow progress in the identification of treatments effective on a wide

range of malignancies, cancer treatment
is now turning to personalized therapies
based in part on pharmacogenomics. By
contrast, aging research is moving in the
opposite direction by searching for common ways to prevent, postpone and treat
a wide range of age-related diseases, based
on the modulation of genetic pathways
that are conserved from yeast to mammals.1 In fact, it may be a solid evolutionary and comparative biology-foundation,
which makes this ambitious goal of biogerontologists a realistic or at least a promising one. On the other hand, the progress
of biogerontology is viewed by many clinicians as too fundamental and far from
translational applications. In most cases,
it is not clear how aging research will be
translated into FDA approved drugs or
treatments that have effects that are superior to those already available or being
developed. For example, it is not clear how
the long-term 20–30% reduction in calorie intake (dietary restriction, DR) that
we and many others before us have shown
to be effective in extending the life span
of model organisms will make humans
live longer or healthier.1-3 Furthermore,
despite the fact that long-term DR was
confirmed to reduce cancer and cardiovascular disease in monkeys4 and to be effective in preventing obesity, type 2 diabetes,
inflammation, hypertension and atherosclerosis, as indicated by the early results
in humans studies,5 it is highly unlikely to
be adopted in its more extreme and effective version by even a small portion of the
population. For example, the 20 to 40%
chronic reduction in daily calorie intake
shown to be effective in retarding cancer
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Figure 1. Average self-reported severity of symptoms in patients that have received chemotherapy with or without fasting.

growth in mice would not be feasible
for cancer therapy for multiple reasons:
(1) the effects of chronic DR in patients
with a clinically evident tumor is expected
to delay but not stop the progression of
the disease6-8 and this delay may only
occur for a portion of the malignancies,9
(2) although weight loss and cachexia
in the early stages of treatment are less
prevalent than commonly thought,10-12
the ~15% loss of BMI and ~30% longterm loss of body fat caused by a moderate
(20%) calorie restriction13 may be tolerated by only a very small portion of cancer
patients receiving treatment, (3) Because
this long-term restriction is accompanied
by delayed wound healing and immunologic impairment in rodents,1,14,15 it is not
clear what risks it may impose on cancer patients receiving treatment.16 Our
studies of DSR, which were triggered by
our fundamental findings that switching yeast cells to water protected them
against a wide range of toxins, started
as a way to address these concerns but
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also as an attempt to achieve a much
more potent therapeutic effect than that
achieved by DR.17,18 Because starvationinduced protection can increase many
fold when combined with modulation
of pro-aging pathways and since it is in
principle blocked by the expression of any
oncogene, it has the potential to provide a
method to allow common chemotherapy
to selectively kill cancer cells, independently of the type of cancer.19-21 The DSR
experiments in mammals were also based
on our hypothesis that stress resistance
and aging regulatory pathways were conserved from yeast to mammals.
We found that fasting for 48 or more
hours or in vitro starvation conditions that
mimic fasting protected mice and/or normal cells but not cancer cells from various
chemotherapy drugs and other deleterious
agents.21 This effect was shown to depend
in part on the reduction of circulating
IGF-I and glucose levels.21,22 Although a
differential regulation of cell division in
normal and cancer cells23,24 is likely to
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contribute to DSR, much of it appears to
be dependent on protective systems which
are normally maintained in an inactive
or low activity state even in non-dividing
cells.1,25 In fact, in non-dividing yeast and
mice, deficiencies in glucose or IGF-I signaling that match those observed after
starvation promote resistance to doxorubicin, a chemotherapy drug that specifically
targets muscle cells in the heart.21,22
As expected, many clinicians were
skeptical of our hypothesis that cancer
treatment could be improved not by a
“magic bullet” but by a “not so magic DSR
shield” as underlined by Leonard Saltz, an
oncologist at Memorial Sloan-Kettering
Cancer Center: “Would I be enthusiastic about enrolling my patients in a trial
where they’re asked not to eat for 2.5 days?
No.”26 However, ten oncologists did allow
their patients, suffering from malignancies ranging from stage II breast cancer
to stage IV esophageal, prostate and lung
malignancies to undergo a 48–140 hours
pre-chemotherapy and a 5–56 hours post
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chemotherapy water-only fast. The six
patients who received chemotherapy with
or without fasting reported a reduction in
fatigue, weakness and gastrointestinal side
effects while fasting27 (Fig. 1). A trend for
a reduction of many additional side effects
was also reported by the group of patients
who always fasted before chemotherapy.27
In those patients whose cancer progression was assessed, chemotherapy was
effective and in some cases it was highly
effective.27 A clinical trial sponsored by
the V-Foundation for Cancer Research,
aimed at testing the safety and efficacy of
a 24 hour fast in combination with chemotherapy, is in its safety stage. Because
it was originally limited to patients diagnosed with bladder cancer the clinical
trial progressed slowly. However, its recent
expansion to include patients receiving
platinum-based chemotherapy (breast,
ovarian, lung cancer), is expected to expedite it. Conclusive results for the effect of a
3–4 day fast on chemotherapy-dependent
side effects and possibly therapeutic index
are not expected to become available for
several years. Even if a more modest effect
than the 1,000-fold differential protection
against oxidative stress and chemotherapy
observed in normal and cancer-like yeast
cells was achieved in humans, this method
could result in long-term survival for many
patients with metastatic cancers, particularly those in which malignant cells have
not acquired multidrug resistance.
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